NFKB1 and Duchenne muscular dystrophy: Therefore, multiple NF-κB inhibitors including Edasalonexent (CAT-1004) and Flavocoxid have been used to reduce inflammation in DMD and are currently in Phase 2 and Phase 3 clinical trials, respectively [26,27].